Pancreatic cancer action network - Join us
Clinical Trial
Finder
Retrieving Trials
Retrieving Trials...

Clinical Trials Search

Request a Healthcare Provider account to access full Trial Finder features.

View Details

An authorized healthcare provider account is required to access features including the ability to save, share, and download trial details. Already have an account? Sign In

Request an Account

183 active and recruiting pancreatic cancer clinical trials

NARROW YOUR RESULTS

Filter Trials

  • Match to Patient

  • Browse Trials

Filter Trials

View "Match to Patient" Filters

Geographic Location

Trials Within

of ZIP Code

Continue

Institution

Continue

Sponsor

Continue

Phase

Continue

Drug Name

Continue

Treatment Modality

Continue

Drug Target

Continue

Line of Treatment

Continue

Type of Pancreatic Cancer

Continue

Stage of Pancreatic Cancer

Continue

Performance Status

Continue

Overall Treatment History

Continue

Treatment for Advanced Disease

To select and apply Advanced Treatment History options to your trial search, Stage III or IV must be selected under ‘Stage of Pancreatic Cancer’ and an ‘Overall Treatment History’ must be selected.

    • Number of Prior Systemic Treatments for Advanced Disease

    • Treatment Received for Advanced Disease

Continue
Request a Healthcare Provider account to access full Trial Finder features.

View Details

An authorized healthcare provider account is required to access features including the ability to save, share, and download trial details. Already have an account? Sign In

Request an Account

183 active and recruiting pancreatic cancer clinical trials

Download Email Print Save

Loading Results...

Pilot Study of Mature Dendritic Cell Vaccination Against Mutated KRAS in Patients With Resectable Pancreatic Cancer
Phase I/Ib, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Patients with Advanced KRASG12C Mutant Solid Tumors
A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma
GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care
Phase I Study of Stereotactic MRI-guided Adaptive Radiation Therapy (SMART) in One Fraction for Inoperable Primary or Metastatic Carcinoma (SMART ONE)
Phase I Study of HBI-2438 in Patients with Advanced Malignant Solid Tumors, including Pancreatic Cancer Tumors Harboring KRAS G12C Mutation
A Phase I, Single-Center, Open-Label, Dose De-escalation and Expansion Study Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma
Phase I, Open-Label, Dose Escalation and Expansion Study of CUE-102 Monotherapy in HLA-A*0201 Positive Patients With WT1 Positive Recurrent/Metastatic Cancers
Phase I Study of ELI-002 in Patients with KRAS Mutated Solid Tumors, including Pancreatic Cancer
Phase l Study of RMC-6236 in Patients with Advanced Solid Tumors, including Pancreatic Cancer Tumors Harboring Specific Mutations in KRAS
Phase I Study of NBTXR3 Activated by Radiotherapy for Locally Advanced or Borderline Resectable Pancreatic Ductal Adenocarcinoma
Early Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of PEEL-224 in Patients With Advanced Solid Tumors, Including Pancreatic Cancer
Phase I Study of Fecal Microbial Transplants in Patients with Pancreatic Cancer
Phase I Study of Intraoperative Radiation Therapy Following Stereotactic Body Radiation Therapy and Multi-agent Chemotherapy in Patients with Localized Pancreatic Cancer
Phase 1a/1b Study of LY3537982 in Patients With KRAS G12C-Mutant Advanced Solid Tumors, including Pancreatic Cancer
High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies
Phase I Study of Pyrvinium Pamoate in Patients with Pancreatic Ductal Adenocarcinoma
Phase I Study of FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors, including Pancreatic Cancer
Phase I Study of PHL Treatment in Patients with Pancreatic Cancer
Phase I/Ib Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T) in Patients with Solid Tumors, including Pancreatic Cancer
Phase I Study of Neoantigen Vaccines in Pancreatic Cancer in the Window Prior to Surgery
Phase I Dose-Escalation Study of CPI-613 (Devimistat) in Combination With Chemoradiation in Patients With Pancreatic Adenocarcinoma
A Phase I/Ib Dose Escalation/Expansion Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors, including Pancreatic Cancer
Phase I/IB Dose Escalation and Cohort Expansion Study of MGC018 in Combination With Checkpoint Inhibitor in Patients with Advanced Solid Tumors, including Pancreatic Cancer
Phase I, Open-Label, Dose Escalation of HBI-2376 in Patients With Advanced Malignant Solid Tumors Harboring KRAS or EGFR Mutations
Phase I, Non-randomized, Open-label, Multi-center Dose Escalation Trial of BI 765049 and BI 765049 + BI 754091 Administered by Repeated Intravenous Infusions in Patients with Malignant Solid Tumors, including Pancreatic Cancer Expressing B7-H6
Phase I Study of TORL-2-307-ADC in Patients with Advanced Solid Tumors, including Pancreatic Cancer
Phase I Study of P-MUC1C-ALLO1 in Patients with Advanced or Metastatic Solid Tumors, including Pancreatic Cancer
Phase I Study of Medical Food for the Dietary Management of Metastatic Pancreatic Cancer (NEAAR)
Phase I Study of SX-682 in Combination with Nivolumab as a Maintenance Therapy in Patients with Metastatic Pancreatic Adenocarcinoma
Phase I Study of First-line L-glutamine with Gemcitabine and Nab-paclitaxel in Patients with Advanced Pancreatic Cancer
Phase I Study of TORL-2-307-MAB in Patients with Advanced Solid Tumors, including Pancreatic Cancer
Phase I Study of Binimetinib and Palbociclib In Patients With Operable KRAS-Positive Lung, Colorectal, or Pancreatic Cancer
Phase I/ Ib Study of NGM831 in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumors, including Pancreatic Cancer
Phase I Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor (CDAi) With Oral Decitabine in Patients with Solid Tumors, including Pancreatic Cancer
Phase I Study Of SY 5609, An Oral, Selective CDK7 Inhibitor, In Adult Patients With Select Advanced Solid Tumors, Including Pancreatic Cancer
Phase Ia/Ib Study Of RSC-1255 In Patients With Advanced Solid Tumor Malignancies, Including Pancreatic Cancer
Phase I Study Of GNX102 In Patients With Advanced Solid Tumors, including Pancreatic Cancer
Phase I Study of Mesenchymal Stromal Cells-Derived Exosomes With KRAS G12D siRNA for Metastatic Pancreas Cancer Patients Harboring KRAS G12D Mutation
Phase I Study of Precision CRT for Liver-Dominant Metastatic Pancreatic Cancer With Homologous Recombination Deficiency (PreCISeRT)
Phase I Study of ProAgio in Patients with Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor Malignancies
Phase IB Trial of Niraparib and TSR-042 in Patients With BRCA-Mutated Breast, Pancreas or Ovary Cancer
A Phase I Study of Gemcitabine, Nab-Paclitaxel, and Bosentan in Patients With Unresectable Pancreatic Cancer
Phase Ib Open-label, Multicenter, Clinical Trial to Evaluate the Safety and Efficacy of Autologous Claudin 18.2 Chimeric Antigen Receptor T-cell Therapy in Patients With Advanced Gastric or Pancreatic Adenocarcinoma
Phase I, First-in-Human Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of (ML-246) in Patients With Metastatic Solid Tumors, including Pancreatic Cancer
Phase I Study of Th-1 Dendritic Cell Immunotherapy in Combination With Standard Chemotherapy for the Adjuvant Treatment of Pancreatic Adenocarcinoma (DECIST)
Early Phase I Study of Lidocaine Infusion in Pancreatic Cancer: Translational Studies in a Preclinical Model And Human Subjects
Phase I Trial of Sonidegib and Pembrolizumab in Advanced Solid Tumors, including Pancreatic Cancer
Phase I Dose Escalation Study of NMS-03305293 in Adult Patients With Selected Advanced/Metastatic Solid Tumors
Phase I Trial of Ulixertinib (BVD-523) and Hydroxychloroquine in Patients With Advanced MAPK-Mutated Gastrointestinal Adenocarcinomas
Phase I Study to Evaluate the Safety and Tolerability of AB680 Combination Therapy in Participants With Gastrointestinal Malignancies
Phase I Study of SOR-C13 in Patients With Advanced Solid Tumors
Phase Ib Trial of Metformin, Digoxin, Simvastatin in Patients With Advanced Pancreatic Cancer and Other Advanced Solid Tumors
Phase I Study of Safety and Immunogenicity of Survivin Long Peptide Vaccine (SurVaxM) in Patients With Metastatic Neuroendocrine Tumors (NETs)
Phase Ib Serial Measurements of Molecular and Architectural Responses to Therapy Trial (SMMART)
Phase I Study of Losartan and Hypofractionated Radiation Therapy After Induction Chemotherapy for Borderline Resectable or Locally Advanced Pancreatic Cancer (SHAPER)
Early Phase I Study of A Window of Opportunity Strategy for Targeted Pathway Inhibition in Patients With Pancreatic Ductal Adenocarcinoma
Phase I Study of Proton Therapy in Adjuvant Pancreatic Cancer (Proton-PANC)
Phase I Study of Molecular-Guided Surgery for Pancreatic and Gastrointestinal Neuroendocrine Cancers
Phase I/Ib Open-Label, Multi-Center, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics and Preliminary Efficacy of Intravenous NBF-006 in Patients With Non-Small Cell Lung, Pancreatic, or Colorectal Cancer
Phase I Study of Concurrent Nab-Paclitaxel + Gemcitabine With Hypofractionated, Ablative Proton Therapy for Locally Advanced Pancreatic Cancer
Phase I Study of Chemotherapy and Irreversible Electroporation (IRE) in the Treatment of Advanced Pancreatic Adenocarcinoma
Phase I, Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 in Patients With Solid Tumors, including Pancreatic Cancer, or Lymphoma
Phase I, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors
Phase I Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors
Phase I Active Immunotherapy Trial With a Combination of Two Chimeric (Trastuzumab-like and Pertuzumab-like)Human Epidermal Growth Factor Receptor 2 (HER-2) B Cell Peptide Vaccine Emulsified in ISA 720 and Nor-MDP Adjuvant in Patients With Advanced Solid Tumors
Phase I Open-label Dose Escalation and Dose Expansion Study of CGX1321 in Patients With Advanced Solid Tumors and Phase Ib Study of CGX1321 in Combination With Pembrolizumab in Patients With Advanced Gastrointestinal Tumors
Phase I Study of Human Monoclonal Antibody 5B1 (MVT-5873) as Monotherapy and With Chemotherapy in Patients With Pancreatic Cancer or Other CA19-9 Positive Malignancies
Phase I Study of Radiation and Nab-Paclitaxel in Patients With Unresectable and Borderline Resectable Pancreatic Cancer
Phase I/II Study of MDK-703 as a Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced or Metastatic Solid Tumors (ORCHID-1)
A Phase 1b/2a Study of Gemcitabine and Nab-paclitaxel in Combination With Avutometinib (VS-6766) and Defactinib in Patients With Previously Untreated Metastatic Adenocarcinoma of the Pancreas
Phase I/II Study, Single Arm, Open Label, of Protein-Bound Paclitaxel, Cisplatin, and Gemcitabine (GCN) Combined With Tumor Treatment Fields (TTF) in Patient With Metastatic Pancreatic Adenocarcinoma
Phase Ib/II Study of ZEN003694 and Entinostat in Advanced and Refractory Solid Tumors and Lymphomas
Phase Ib/III Global, Randomized, Controlled, Open-label Trial Comparing Treatment With RYZ101 to Standard of Care Therapy in Patients With Inoperable, Advanced, SSTR+, Well-differentiated GEP-NETs That Have Progressed Following Prior 177Lu-SSA Therapy
A Phase I/II Single Arm Open-Label Clinical Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
Phase I/II Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors, including Pancreatic Cancer
Phase I/II Study of CBX-12 in Patients with Advanced or Metastatic Refractory Solid Tumors
Phase I/II Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Patients with Advanced Solid Tumors, including Pancreatic Cancer
Phase I/II Study of Sonoporation and Chemotherapy in Patients with Pancreatic Cancer
Phase I/II Study of BNT141 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With CLDN18.2-positive Solid Tumors, including Pancreatic Cancer
Phase I/II Study of HCW9218 in Patients with Advanced Pancreatic Cancer
Phase I/II, Open-Label, Single-Arm, Dose-Escalation and Dose-Expansion Study of the Safety, Tolerability, Pharmacokinetic, and Antitumor Activity of E-602 as a Single Agent and in Combination With Pembrolizumab in Patients with Solid Tumors, including Pancreatic Cancer (GLIMMER-01)
Phase I/II Study of CEND-1 In Combination With Neoadjuvant FOLFIRINOX in Patients with Solid Tumors, including Pancreatic Cancer (CENDIFOX)
Phase I/II of XB2001 (Anti-IL-1a True Human Antibody) in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Patients with Advanced Pancreatic Cancer (1-BETTER)
Phase I/II Study of of MRTX1719 in Patients with Advanced Solid Tumors With MTAP Homozygous Deletion
Phase I Study of ABTL0812 in Combination with FOLFIRINOX for First-line Treatment in Patients with Metastatic Pancreatic Cancer
Phase I-II Trial of AGuIX Gadolinium-based Nanoparticles With Stereotactic Magnetic Resonance-guided Adaptive Radiation Therapy for Centrally Located Lung Tumors and Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma
Phase I/II Study Of Autologous T Cells To Express T-Cell Receptors (TCRs) In Patients With Solid Tumors, Including Pancreatic Cancer
Phase I/ II Study of GEN1042 in Patients with Malignant Solid Tumors, including Pancreatic Cancer
Phase I/II Study Of Neoadjuvant mFOLFIRINOX In Combination With Peri-Operative Oral Hydroxychloroquine (FHQ) In Patients With Resectable Adenocarcinoma Of The Pancreas
Phase I/II Multi-Center, Open Label Study of CYT-0851, an Oral RAD51 Inhibitor, in Patients With Relapsed/Refractory B-Cell Malignancies and Advanced Solid Tumors, including Pancreatic Cancer
Phase I/II Master Protocol of Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy (SMART)
Phase Ib/IIa Open-label Study of NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Patients With Relapsed/Refractory Advanced Solid Tumors, including Pancreatic Cancer
Phase I/II Trial in Patients With Metastatic Gastrointestinal Epithelial Cancer Administering Tumor-Infiltrating Lymphocytes in Which the Gene Encoding CISH Was Inactivated Using the CRISPR/Cas9 System
Phase I/II Study of Neratinib and Divalproex Sodium (Valproate) in Advanced Solid Tumors, With an Expansion Cohort in Ras-Mutated Cancers
Phase I/II Trial of Combination Immunotherapy With Nivolumab and a CCR2/CCR5 Dual Antagonist (BMS-813160) With or Without GVAX Following Chemotherapy and Radiotherapy for Locally Advanced Pancreatic Ductal Adenocarcinomas (PDACs)
Phase Ib/II Study of the Microenvironment Modifier L-DOS47 Plus Doxorubicin for the Treatment of Patients With Previously Treated Advanced Pancreatic Cancer
Phase I/II Trial of GP-2250 in Combination With Gemcitabine in Pancreatic Adenocarcinoma After FOLFIRINOX Chemotherapy
Phase I/II Study of MCLA-128, a Full Length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients With Solid Tumors (eNRGy Trial)
Phase I/II, Open-label, Multi-center Study of the Safety and Efficacy of KY1044 as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies
Phase I/II Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3B) Inhibitor, as a Single Agent and Combined With Chemotherapy, in Patients With Refractory Hematologic Malignancies or Solid Tumors
Phase Ib/II Treatment of Advanced Pancreatic Cancer With Anti-CD3 x Anti-EGFR-Bispecific Antibody Armed Activated T-Cells (BATs)
Phase I/IIa, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of PEN-866 in Patients With Advanced Solid Malignancies
Phase I/II Study to Evaluate the Safety and Efficacy of the Permanently Implantable LDR CivaSheet® in Combination With External Beam Radiation in the Treatment of Pancreatic Cancer
Phase I/IIa Trial Evaluating Safety of LOAd703, an Armed Oncolytic Adenovirus for Pancreatic Cancer
Phase I/II Trial of Stereotactic Body Proton Therapy for Patients With Liver Metastases
Phase II Parallel Group Study to Evaluate the Safety, Pharmacokinetics, and Dose Response of Paltusotine Treatment in Patients with Carcinoid Syndrome
Phase II Study of Evaluating the Efficacy and Safety of Tusamitamab Ravtansine (SAR408701) Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors, including Pancreatic Cancer
A Phase II Study With Combination Chemotherapy (Gemcitabine and Nab-Paclitaxel), Chemokine (C-X-C) Motif Receptor 4 Inhibitor (BL-8040), and Immune Checkpoint Blockade (Cemiplimab) in Metastatic Treatment naïve Pancreas Adenocarcinoma
Phase II Study of Niraparib and TSR-042 in Patients with Germline or Somatic BRCA1/2 and PALB2-Related Pancreatic Cancer
Phase II Trial of ERK Inhibition Alone and in Combination With Autophagy Inhibition in Patients with Metastatic Pancreatic Cancer
Phase II Study of Neoadjuvant FOLFIRINOX in Patients with Non-Metastatic Pancreatic Cancer
Phase II Trial of Lenvatinib-Pembrolizumab Maintenance Therapy in Patients With Advanced Unresectable Pancreatic Cancer
Phase II study of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors
Phase II Study of FOLFIORINOX in Older Pancreatic Cancer Patients
Phase II Study of Pemigatinib in Patients With Adenosquamous Carcinoma of the Pancreas
Phase II Study of Lutetium Lu 177 Dotatate PRRT Versus Capecitabine and Temozolomide in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumors
A Phase II Pilot Clinical Trial of Lurbinectedin in Patients With Advanced Pancreatic Cancer With DNA Repair Mutations
Phase II Trial of Paricalcitol and Hydroxychloroquine (PH) Combination With Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer
Phase II Study of Digoxin in Combination with FOLFIRINOX in Patients with Resectable Pancreatic Cancer
Phase II Study of FOLFIRINOX Alternated with Biweekly Gemcitabine Plus Nab-Paclitaxel in Patients with Untreated Metastatic Adenocarcinoma
Phase II Study of Adaptive Switching of FOLFIRINOX or Gemcitabine/Nab-Paclitaxel as a Neoadjuvant Strategy for Patients with Resectable and Borderline Resectable/Locally Advanced Unresectable Pancreatic Cancer (NeoOPTIMIZE)
Phase II Study of Cabozantinib and Pembrolizumab in Patients with Metastatic Pancreatic Cancer
Phase II Study of Neoadjuvant Gemcitabine, Nab-paclitaxel, Durvalumab (MEDI4736) (Anti-PD-L1), and Oleclumab (Anti-CD73) in the Treatment of Resectable/Borderline Resectable Primary Pancreatic Adenocarcinoma
Phase II Study Of Niraparib In Patients With PALB2 Mutated Locally Advanced Or Metastatic Solid Tumors, Including Pancreatic Cancer
Phase II Study of Vemurafenib in Combination with Sorafenib in Patients with Advanced KRAS G12D Mutated Pancreatic Cancer
Phase II Study of Atezolizumab and Cabozantinib in Patients with Metastatic Pancreatic Cancer
Phase II Study Of Nivolumab and Relatlimab In Advanced Mismatch Repair Deficient Cancers Resistant To Prior PD-(L)1 Inhibitor, Including Pancreatic Cancer
Phase II Study of Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma
Phase II Trial of Endoscopic Ultrasound Pancreatic Cancer Radiofrequency Ablation (PANCARDINAL-1 Trial)
Phase II Study of the Safety, Efficacy, and Immune Response of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Patients With Previously Treated Metastatic Pancreatic Adenocarcinoma
Phase Ib/II, Randomized, Controlled, Open-Label Study Evaluating the Safety and Efficacy of ABBV-927 Administered in Combination With Modified FOLFIRINOX (mFFX) With or Without Budigalimab Compared to mFFX in Patients With Untreated Metastatic Pancreatic Adenocarcinoma
Phase II Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, Formerly PT2977) Monotherapy in Participants With Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), or Von Hippel-Lindau (VHL) Disease-Associated Tumors
Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients With Germline BRCA1 or BRCA2 Mutations
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Multi-agent Low Dose Chemotherapy (Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, Irinotecan) Followed by Maintenance Olaparib and Pembrolizumab in Untreated Metastatic Pancreatic Ductal Adenocarcinoma
A Phase II Trial of Binimetinib in Combination With Encorafenib in Patients With Pancreatic Malignancies and a Somatic BRAFV600E Mutation
Phase II Trial of the Superenhancer Inhibitor Minnelide in Advanced Refractory Adenosquamous Carcinoma of the Pancreas (ASCP)
Phase II Study of Perbrolizumab Plus Lenvatinib in Combination with Belzutifan in patients with Solid Tumors (MK-4682-016), including Pancreatic Cancer
Phase II Study of Pancreatic Adenocarcinoma Signature Stratification for Treatment (PASS-01)
Phase II Trial for The Prevention of Progression to Pancreatic Cancer Trial (The 3P-C Trial): Preventing an Incurable Disease
Phase II Study of Hypofractionated Radiation Therapy to Augment Immune Response in Patients With Metastatic Gastrointestinal Malignancies Progressing on Immune Therapy (ARM-GI)
Phase IIa, Dose-Finding Study of Ad5.F35-hGCC-PADRE Vaccine in Adults With Gastrointestinal Adenocarcinomas at Risk of Relapse Post Definitive Surgery and Standard Therapy
Phase IIb, Randomized Study of GC4711 in Combination With Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Unresectable or Borderline Resectable Nonmetastatic Pancreatic Cancer (GRECO-2)
Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in People With Metastatic Cancer, including Pancreatic Cancer
Phase II Randomized Study of Gemcitabine and Nab-Paclitaxel Compared With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients With Treatment Naive Metastatic Pancreatic Cancer (GIANT)
Phase II, Open-label, Randomized, Comparative Study of Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer
Phase II Trial of INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic or Ampullary Cancer
Phase II Study to Evaluate the Efficacy and Safety of Adoptive Transfer of Autologous Tumor Infiltrating Lymphocytes in Patients With Advanced Solid Cancers, including Pancreatic Cancer
Phase II Trial of Pre-operative Chemotherapy (With Gemcitabine and Nab-Paclitaxel) and Stereotactic Body Radiotherapy Followed by Surgery and Chemotherapy in Patients With Resectable Pancreatic Adenocarcinoma
Phase II Open Label Trial Galeterone Alone or Galeterone Combined With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Standard Chemotherapy (1911GCCC)
Phase II Study to Evaluate Modified Folfirinox and Stereotactic Body Radiation Therapy in Non-metastatic Unresectable Pancreatic Adenocarcinoma
Phase II Single-Arm Study of Nanoliposomal Irinotecan With Fluorouracil and Leucovorin in Refractory Advanced High Grade Neuroendocrine Cancer of GI, Unknown or Pancreatic Origin
Registry to Evaluate Effectiveness and Safety of the NanoKnife System for the Ablation of Stage III Pancreatic Adenocarcinoma (DIRECT)
Phase II, Open-Label, Randomized Study to Assess the Antitumor Activity and Safety of Zolbetuximab (IMAB362) in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Patients With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma
Phase II Trial of Hepatic Artery Infusional Floxuridine With Systemic Chemotherapy in the Treatment of Pancreatic Cancer Liver Metastases
Phase II Trial of the CDK4/6 Inhibitor Abemaciclib in Patients With Advanced and Refractory Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors (GEP NETs)
Phase II Randomized Study of Pembrolizumab With or Without Defactinib, a Focal Adhesion Kinase Inhibitor Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma (PDAC)
Phase II Evaluation of the Effect of 2 Versus 6 Hour Oxaliplatin Infusions on Neuropathy and Pharmacokinetics in Patients With Gastrointestinal Cancers
Phase II Trial of Pharmacological Ascorbate, Gemcitabine, and Nab-Paclitaxel for Metastatic Pancreatic Cancer (PACMAN 2.1)
Phase II Study of Electron Beam Intraoperative Radiation Therapy Following Chemoradiation in Patients With Pancreatic Cancer With Vascular Involvement: PACER (Pancreatic AdenoCarcinoma With Electron Intraoperative Radiation Therapy)
Phase II Trial of Stereotactic Body Radiation Therapy or Conventionally Fractionated Concurrent Chemotherapy and Radiation Therapy Preoperatively for Resectable or Borderline Resectable Pancreatic Adenocarcinoma
Phase II Adaptive Modification of Neoadjuvant Therapy Based on Clinical Response in Patients With Localized Pancreatic Cancer
Phase II Trial of Niraparib in Metastatic Pancreatic Cancer After Previous Chemotherapy (NIRA-PANC)
Phase II Study of High Dose Vitamin C Intravenous Infusion in Patients With Resectable or Metastatic Solid Tumor Malignancies (Cohort B)
Phase II Study of High Dose Vitamin C Intravenous Infusion in Patients With Resectable or Metastatic Solid Tumor Malignancies (Cohort A)
Phase II, Prospective, Multinational, Multi-Center, Single-Arm, Open-Label Study Evaluating the Efficacy, Safety and Tolerability of siG12D-LODER in Combination With Standard of Care Chemotherapy in the Treatment of Patients With Locally Advanced Pancreatic Cancer (PROTACT)
Phase II Randomized Study of the Efficacy and Safety of Hypofractionated Stereotactic Radiotherapy and 5FU or Capecitabine With and Without Zometa in Patients With Locally Advanced Pancreatic Cancer
Phase II Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Patients With Advanced Solid Tumors (KEYNOTE 158),
Phase II Targeted Agent and Profiling Utilization Registry Study (TAPUR)
Phase II Platform Study of Combination Immunotherapy for the Neoadjuvant and Adjuvant Treatment of Patients With Surgically Resectable Adenocarcinoma of the Pancreas
Phase II Trial of Escalated Dose Proton Radiotherapy With Elective Nodal Irradiation and Concomitant Chemotherapy for Patients With Unresectable, Borderline Resectable or Medically Inoperable Pancreatic Adenocarcinoma
Phase II Study of Cisplatin, Carboplatin and Etoposide Versus Temozolomide and Capecitabine in Advanced Gastroenteropancreatic Neuroendocrine Carcinomas
Phase II Study of Combined Targeted p53 Gene Therapy (SGT-53) Plus Gemcitabine/Nab-Paclitaxel for Treatment of Metastatic Pancreatic Cancer
Phase II Study Using FOLFIRINOX and Stereotactic Body Radiation Therapy for Locally Advanced, Non-Resectable Pancreatic Cancer
Phase II/III Study of Nab-Paclitaxel and Gemcitabine with or without SBP-101 in Patients with Metastatic Pancreatic Cancer
A Prospective, Randomised, Controlled, Open-label, Multicentre Study to Evaluate Efficacy, Safety and Patient-Reported Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-Edotreotide Compared to Best Standard of Care in Patients With Well-differentiated Aggressive Grade 2 and Grade 3, Somatostatin Receptor-Positive (SSTR+), Neuroendocrine Tumours of GastroEnteric or Pancreatic Origin
Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer
Phase III Randomized, Multicenter, Controlled, Unblinded Study to Assess the Safety and Efficacy of the NanoKnife® System for the Ablation of Unresectable Stage III Pancreatic Adenocarcinoma (DIRECT)
Phase III Randomized, Double-Blinded Study of Cabozantinib Versus Placebo in Patients With Advanced Neuroendocrine Tumors After Progression on Prior Therapy (CABINET)
Phase III Trial of Targeted Intra-arterial Gemcitabine vs. Continuation of IV Gemcitabine Plus Nab-Paclitaxel Following Induction With Sequential IV Gemcitabine Plus Nab-Paclitaxel and Radiotherapy for Locally Advanced Pancreatic Cancer (TIGeR-PaC)
Phase III Trial to Assess the Survival Impact of Extensive Peritoneal Lavage Using Distilled Water or Saline at High Volumes After Pancreatic Resection for Pancreatic Ductal Adenocarcinoma (WASH Trial)
Phase III Study of the Efficacy and Safety of Glufosfamide Compared with Fluorouracil (5-FU) in Patients with Metastatic Pancreatic Adenocarcinoma Previously Treated with Gemcitabine
Download Email Print Save

We are committed to providing the most accurate and complete trial information. However, we cannot guarantee it. If you would like to report an incorrect piece of information, please contact our administrator.

SHARE THE CLINICAL TRIAL FINDER

JOIN THE CONVERSATION

Privacy Policy
Copyright © 2007–2023 Pancreatic Cancer Action Network

ABOUT US

The Pancreatic Cancer Action Network (PanCAN) is dedicated to fighting the world’s toughest cancer. In our urgent mission to save lives, we attack pancreatic cancer on all fronts: research, clinical initiatives, patient services and advocacy. Our effort is amplified by a nationwide network of grassroots support. We are determined to improve patient outcomes and accelerate progress.

Learn More About Us

Honors & Accreditations

  • Charity Navigator

CONTACT US

No organization supports pancreatic cancer patients like we do. Through our Patient Services, we provide more resources and speak with more patients and caregivers than any other pancreatic cancer organization in the world.

Contact Us